Neil E. Kay, M.D.
Neil E. Kay, M.D.
The laboratory research of Neil E. Kay, M.D., is focused on B-chronic lymphocytic leukemia (CLL). This most common and still incurable leukemia is not fully understood in terms of both its clinical and biologic heterogeneity.
However, because it is both a frequently diagnosed leukemia and provides ready access to leukemic cells, it proves to be an ideal tumor model for a variety of in vitro studies. To support the laboratory studies described below, Dr. Kay and his colleagues have established an extensive CLL tissue bank and clinical database that is a rich, nationally recognized resource for CLL studies.
Dr. Kay's work involves close collaboration with several other talented scientists at Mayo Clinic, including Diane F. Jelinek, Ph.D., in the Department of Immunology; Curtis A. Hanson, M.D., and Daniel L. Van Dyke, Ph.D., in the Department of Laboratory Medicine and Pathology; James R. Cerhan, M.D., Ph.D., in the Division of Epidemiology; and Susan L. Slager, Ph.D., in the Division of Biomedical Statistics and Informatics.
This collaboration has provided for unique studies in CLL that now include extramurally funded studies in CLL B-cell signaling, detailed epidemiological studies of CLL and genome-wide analysis of familial CLL patients (CLL families with two or more CLL patients).
Dr. Kay is also very involved in the design and implementation of CLL clinical trials for previously untreated and treated CLL patients that incorporate the latest novel drugs alone or in combinations. These trials are conducted within the national cooperative group system of the United States.
Significance to patient care
Dr. Kay and his colleagues have accumulated a large database of both clinical information and tissue samples (such as blood and marrow) from CLL patients. The latter effort is able to collect valuable information on critical biologic and prognostic features of CLL patients that can be correlated with their clinical outcomes. The work that stems from this database provides information on strategies for unique therapies.
This project was started almost from the outset of Dr. Kay's tenure at Mayo Clinic, which began 12 years ago. It continues to be a rich resource for the clinical, translational and basic biologic research of Dr. Kay and his colleagues. Their clinical trials portfolio is extensive in that they have approaches that try to encompass all cohorts of CLL patients, from those with early-stage disease to those with more advanced stages of disease.
Department of Immunohematology
Department of Hematology
Department of Internal Medicine
Department of Medicine
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.